Cargando…

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study

BACKGROUND: Randomized controlled clinical trials have shown vortioxetine to be efficacious and well tolerated for the treatment of major depressive disorder (MDD). The Real-Life Effectiveness of Vortioxetine in Depression (RELIEVE) study was undertaken to demonstrate the effectiveness and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mattingly, Gregory W., Ren, Hongye, Christensen, Michael Cronquist, Katzman, Martin A., Polosan, Mircea, Simonsen, Kenneth, Hammer-Helmich, Lene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959350/
https://www.ncbi.nlm.nih.gov/pubmed/35356713
http://dx.doi.org/10.3389/fpsyt.2022.824831
_version_ 1784677134444265472
author Mattingly, Gregory W.
Ren, Hongye
Christensen, Michael Cronquist
Katzman, Martin A.
Polosan, Mircea
Simonsen, Kenneth
Hammer-Helmich, Lene
author_facet Mattingly, Gregory W.
Ren, Hongye
Christensen, Michael Cronquist
Katzman, Martin A.
Polosan, Mircea
Simonsen, Kenneth
Hammer-Helmich, Lene
author_sort Mattingly, Gregory W.
collection PubMed
description BACKGROUND: Randomized controlled clinical trials have shown vortioxetine to be efficacious and well tolerated for the treatment of major depressive disorder (MDD). The Real-Life Effectiveness of Vortioxetine in Depression (RELIEVE) study was undertaken to demonstrate the effectiveness and safety of vortioxetine for the treatment of MDD in routine clinical practice. METHODS: RELIEVE was a 24-week, observational, prospective cohort study in outpatients with MDD initiating treatment with vortioxetine at their physician's discretion in routine care settings in Canada, France, Italy, and the USA (NCT03555136). The primary study outcome was patient functioning assessed by the Sheehan Disability Scale (SDS). Secondary outcomes included depression severity [9-item Patient Health Questionnaire (PHQ-9)], cognitive symptoms [5-item Perceived Deficits Questionnaire-Depression (PDQ-D-5)], and cognitive performance [Digit Symbol Substitution Test (DSST)]. Mixed models of repeated measures were used to assess change from baseline at week 24, adjusted for relevant confounders. RESULTS: A total of 737 patients were eligible for inclusion in the full analysis set. Most patients (73.7%) reported at least one comorbid medical condition, 56.0% had comorbid anxiety and 24.4% had comorbid generalized anxiety disorder. Improvement in least-squares (LS) mean SDS score from baseline to week 24 was 8.7 points. LS mean PHQ-9, PDQ-D-5 and DSST scores improved by 7.4, 4.6, and 6.2 points, respectively. Adverse events were observed in 21.2% of patients [most commonly, nausea (8.2% of patients)]. CONCLUSIONS: These results demonstrate the effectiveness and tolerability of vortioxetine for the treatment of MDD in a large and heterogeneous patient population representative of that encountered in routine clinical practice.
format Online
Article
Text
id pubmed-8959350
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89593502022-03-29 Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study Mattingly, Gregory W. Ren, Hongye Christensen, Michael Cronquist Katzman, Martin A. Polosan, Mircea Simonsen, Kenneth Hammer-Helmich, Lene Front Psychiatry Psychiatry BACKGROUND: Randomized controlled clinical trials have shown vortioxetine to be efficacious and well tolerated for the treatment of major depressive disorder (MDD). The Real-Life Effectiveness of Vortioxetine in Depression (RELIEVE) study was undertaken to demonstrate the effectiveness and safety of vortioxetine for the treatment of MDD in routine clinical practice. METHODS: RELIEVE was a 24-week, observational, prospective cohort study in outpatients with MDD initiating treatment with vortioxetine at their physician's discretion in routine care settings in Canada, France, Italy, and the USA (NCT03555136). The primary study outcome was patient functioning assessed by the Sheehan Disability Scale (SDS). Secondary outcomes included depression severity [9-item Patient Health Questionnaire (PHQ-9)], cognitive symptoms [5-item Perceived Deficits Questionnaire-Depression (PDQ-D-5)], and cognitive performance [Digit Symbol Substitution Test (DSST)]. Mixed models of repeated measures were used to assess change from baseline at week 24, adjusted for relevant confounders. RESULTS: A total of 737 patients were eligible for inclusion in the full analysis set. Most patients (73.7%) reported at least one comorbid medical condition, 56.0% had comorbid anxiety and 24.4% had comorbid generalized anxiety disorder. Improvement in least-squares (LS) mean SDS score from baseline to week 24 was 8.7 points. LS mean PHQ-9, PDQ-D-5 and DSST scores improved by 7.4, 4.6, and 6.2 points, respectively. Adverse events were observed in 21.2% of patients [most commonly, nausea (8.2% of patients)]. CONCLUSIONS: These results demonstrate the effectiveness and tolerability of vortioxetine for the treatment of MDD in a large and heterogeneous patient population representative of that encountered in routine clinical practice. Frontiers Media S.A. 2022-03-09 /pmc/articles/PMC8959350/ /pubmed/35356713 http://dx.doi.org/10.3389/fpsyt.2022.824831 Text en Copyright © 2022 Mattingly, Ren, Christensen, Katzman, Polosan, Simonsen and Hammer-Helmich. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Mattingly, Gregory W.
Ren, Hongye
Christensen, Michael Cronquist
Katzman, Martin A.
Polosan, Mircea
Simonsen, Kenneth
Hammer-Helmich, Lene
Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study
title Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study
title_full Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study
title_fullStr Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study
title_full_unstemmed Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study
title_short Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study
title_sort effectiveness of vortioxetine in patients with major depressive disorder in real-world clinical practice: results of the relieve study
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959350/
https://www.ncbi.nlm.nih.gov/pubmed/35356713
http://dx.doi.org/10.3389/fpsyt.2022.824831
work_keys_str_mv AT mattinglygregoryw effectivenessofvortioxetineinpatientswithmajordepressivedisorderinrealworldclinicalpracticeresultsoftherelievestudy
AT renhongye effectivenessofvortioxetineinpatientswithmajordepressivedisorderinrealworldclinicalpracticeresultsoftherelievestudy
AT christensenmichaelcronquist effectivenessofvortioxetineinpatientswithmajordepressivedisorderinrealworldclinicalpracticeresultsoftherelievestudy
AT katzmanmartina effectivenessofvortioxetineinpatientswithmajordepressivedisorderinrealworldclinicalpracticeresultsoftherelievestudy
AT polosanmircea effectivenessofvortioxetineinpatientswithmajordepressivedisorderinrealworldclinicalpracticeresultsoftherelievestudy
AT simonsenkenneth effectivenessofvortioxetineinpatientswithmajordepressivedisorderinrealworldclinicalpracticeresultsoftherelievestudy
AT hammerhelmichlene effectivenessofvortioxetineinpatientswithmajordepressivedisorderinrealworldclinicalpracticeresultsoftherelievestudy